^
Association details:
| Biomarker: | TP53 deletion |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Zydelig (idelalisib) (PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
...it is recommended that patients with TP53 deletion/mutation are treated with novel inhibitors (ibrutinib; idelalisib and rituximab) in front-line and relapse settings.
DOI:
10.1093/annonc/mdv303
Source:
Title:
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia
Excerpt:
The ORR for the 13 subjects with del17p and/or TP53 mutation who had a median of 5 prior regimens, and 85% of whom were refractory to their most recent prior regimen, was 54% (7/13), and the median PFS was 3 months. Of this subgroup, 7 subjects were treated at doses of ≥150 mg bid, and their median PFS was 5 months....This study demonstrates the clinical utility of inhibiting the PI3Kδ pathway with idelalisib.
DOI:
10.1182/blood-2013-11-535047
Trial ID:
